Trametinib, an inhibitor of MEK in the MAPK kinase pathway, did not have a direct cytotoxic effect on CLL cells but inhibited the maturation of monocytes into NLCs. Here, MAP2K7 is linked to B-cell chronic lymphocytic leukemia.